Following China's Two Sessions, executives from world-leading pharmaceutical companies visited Beijing to explore new opportunities. For the first time, biomedicine has been designated as an emerging pillar industry, as China accelerates efforts to build a "Healthy China" by 2035.

Major investments, including Eli Lilly's $3 billion plan and AstraZeneca's about$14 billion commitment, underscore the strong appeal of the Chinese market for global drugmakers.